BIO.NRW COVID-19
Information and
Contact Platform
Current information in connection with the COVID-19 pandemic
At this point BIO.NRW offers all companies and scientists in NRW a platform with actual informations in connection with the COVID-19 pandemic. This includes support programs and funding from the state, the federal government and the EU as well as relevant news from companies and science.
In addition, we also offer you the possibility of individual cooperation and contact requests: If you have offers for your (product) development regarding COVID-19 in the fields of diagnostics, therapy, prevention, clinical studies or in a broader sense to medical technology solutions and/or are looking for partners, please feel free to contact us via email at bio.nrw@bio.nrw.de.
We will publish your offers and/or requests in this area. In case you do not wish to publish your information, you are nevertheless welcome to contact the office so that we can support you while maintaining confidentiality.
Click here for the contact form.
Corona platform of the EU with information on funding opportunities related with Covid-19
Weiterlesen …
Overview of COVID-19 associated (and general) funding, financing, information
Weiterlesen …
COVID-19 News
DiosCURE Announces Exclusive Worldwide License Agreement for Nanobodies Against COVID-19
Accelerated preclinical development of lead candidate DIOS-203 allows for upcoming initiation of first-in-man Phase I study DiosCURE Therapeutics SE announced today that it has signed an exclusive licensing...
Fast SARS-CoV-2 RNA extraction for high-throughput
BioEcho developed a rapid extraction protocol that reduces the isolation of SARS-CoV-2-RNA to just a few minutes. The speed of the extraction method contributes to faster COVID-19 assays as well as increased...
antibodies-online SARS-CoV-2 Handbook
In order to overcome the ongoing COVID-19 pandemic, it is essential to understand the underlying biology of SARS-CoV-2, the causative agent, as well as that of the host's response. antibodies-online has compiled...
Coronavirus: Commission mobilises €123 million for research and innovation to combat the threat of variants
The Commission is mobilising €123 million from Horizon Europe, the new EU research and innovation programme, for urgent research into coronavirus variants. This first emergency funding under Horizon Europe adds to a...
Vaccines: Commission hosts first EU matchmaking event to mobilise Europe’s full potentialfor the production of COVID-19 vaccines
Today, the Commission is hosting the first pan-European matchmaking event with over 300participating companies from 25 Member States to expand COVID-19 vaccine production capacitiesacross Europe and address...
Covid-19: EMA recommends conditional approval for Janssen vaccine
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that the single-dose SARS.CoV.2 vaccine developed by Janssen Pharmaceutical Companies of Johnson &...
European Commission authorises fourth vaccine against COVID-19
Press release March 11 Today, the European Commission has granted a conditional marketing authorisation (CMA) for the COVID‑19 vaccine developed by Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical...
Cologne’s university medicine to coordinate EU vaccine research network VACCELERATE
New consortium of research institutions will coordinate vaccine trials in the European Union / The long-term goal is to strategically plan and carry out vaccine trials in all EU and EU-associated countries The...
EU-Commission establishs HERA Incubator
EU-Commission has proposed an European bio-defence preparedness plan against COVID-19 variants, the so called “HERA Incubator”. With this immediate action Europe shall be prepared for the increased threat of...
Evonik strengthens strategic partnership with BioNTech on COVID-19 vaccine
Establishment of additional lipid production in Germany for use with mRNA-based vaccines Expansion of leading positionas integrated developmentand manufacturing partner in celland gene therapies Increased supply...
Positive interim phase 1/2a data on Janssen’s COVID19 vaccine candidate.
The New England Journal of Medicine (NEJM) has published interim phase 1/2a data for Janssen’s Covid19 vaccine candidate. They show that the vaccine candidate (JNJ-78436735), which is being developed by Johnson & Johnson’...
DiosCURE to Develop Highly Specific Single-Chain Antibodies Against SARS-CoV-2
Core technology includes promising bivalent single-domain antibodies simultaneously targeting two surface structures of the viral spike protein. Lead candidates DIOS-202 and DIOS-203 are engineered for high potency...
CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
Bayer to support CureVac in numerous areas, including development and supply of CVnCoV, they plan to facilitate the supply of several hundred million doses.
...
Phase II Clinical Trial of the COVID-19 Vaccine of Janssen Authorised in Germany
The Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, has approved the Phase II clinical trial of the SARS-CoV-2 vaccine candidate Ad26 COV2.S by Janssen against COVID-19 in Germany. The phase...
QIAGEN to launch rapid portable test that can detect active infections of SARS-CoV-2 in less than 15 min
Access Anti-SARS-CoV-2 Antigen Test, developed in collaboration with Ellume, is easy to use and provides accurate results in less than 15 minutes…
...NRW against Covid-19
In this map you will find a selection of companies and start-ups developing either therapies, vaccines or diagnostics for COVID-19 in North Rhine-Westphalia.
Mit dem Laden der Karte akzeptieren Sie die Datenschutzerklärung von Google.
Mehr erfahren